Oral Proteins & Peptides Market

1
Oral Proteins Peptides Market Trends and
Forecast Till 2030
sales_at_delvens.com www.delvens.com
2
Oral Proteins Peptides Market Trends and
Forecast Till 2030
Oral Proteins Peptides Market, by Molecule
(Semaglutide, Linaclotide, Calcitonin), Drug
Class (GLP-1 Receptor Agonist, GEP, CGRP),
Therapeutic Area (Diabetes, Gastroenterology,
Genetic Disorder), Formulation (Tablet, Capsule)
and region (North America, Europe, Asia-Pacific,
Middle East and Africa and South
America).
Request For Free Sample Report
https//www.delvens.com/get-free-sample/oral-prote
ins-peptides-market
sales_at_delvens.com
www.delvens.com
3
Market Overview
The global Oral Proteins Peptides Market size
was estimated at USD 7,350 million in 2023 and is
projected to reach USD 33,318.8 million in 2030
at a CAGR of 24.10 during the forecast period
2024-2030. The oral proteins and peptides market
refer to the development and utilization of
proteins and peptides delivered orally as
therapeutic agents or nutritional supplements.
These biomolecules are critical in various
medical and healthcare applications, offering
solutions for metabolic disorders, malnutrition,
and chronic diseases. The market is gaining
prominence as the demand for non-injection-based
treatments increases, making oral protein and
peptide formulations an attractive alternative to
conventional injectable therapies. Purchase this
Report https//www.delvens.com/checkout/oral-prot
eins-peptides-market
sales_at_delvens.com
www.delvens.com
4
Key Findings
The glucagon-like peptide-1 (GLP-1) receptor
agonist segment led the market by drug class. The
drug class includes glycine-proline-glutamate
(GPE) analogues, GLP-1 receptor agonists,
guanylate cyclase-C agonists, calcineurin-inhibito
r immunosuppressants, calcitonin gene-related
peptide (CGRP) receptor antagonists, and others. 
By end user, home care settings are projected to
experience the highest growth. The oral proteins
and peptides market is divided into home care
settings, long-term care facilities, and
hospitals specialty clinics. In 2023, the home
care settings segment is expected to register the
highest compound annual growth rate (CAGR). This
growth is driven by increasing awareness, ease of
use, and the effectiveness of these drugs in
treating conditions like diabetes,
gastrointestinal disorders (e.g., IBD and
constipation), and central nervous system
disorders.
sales_at_delvens.com
www.delvens.com
5
Key Findings
The market is also divided into various regions
such as North America, Europe, Asia-Pacific,
South America, and Middle East and Africa. North
America region is projected to hold the largest
market share. Factors such as Increasing
prevalence of chronic diseases, growing geriatric
population, rising demand for non-injection
therapies, advancements in drug delivery
technologies, growing consumer awareness about
health and wellness, expanding healthcare
infrastructure, increased focus on personalized
medicine, rising adoption of functional foods and
dietary supplements, technological innovations in
peptide synthesis, high patient compliance with
oral administration have triggered the Oral
Proteins Peptides Market in the
region. Inquire Before Buying
https//www.delvens.com/Inquire-before-buying/oral
-proteins-peptides-market
sales_at_delvens.com
www.delvens.com
6
Competitive Landscape

• Novo Nordisk A/S
• AbbVie Inc.
• Pfizer Inc.
• Bausch Health Companies Inc.
• Chiesi Farmaceutici S.p.A.
• Acadia Pharmaceuticals Inc.
• Aurinia Pharmaceuticals Inc.
• Merck Co., Inc.
• Johnson Johnson Services, Inc.
• SWK Holdings
• R-Pharm JSC
• Entera Bio Ltd.

sales_at_delvens.com
www.delvens.com
7
Recent Developments

• In September 2023, EnteraBio entered into a
  research collaboration agreement with OPKO
  Biologics, Inc. As part of the agreement, OPKO
  will supply its proprietary long-acting GLP-2
  peptide and select Oxyntomodulin analogs to
  develop oral tablet formulations. This
  collaboration aims to advance innovative
  treatments for various medical conditions.
• In April 2023, Chiesi Farmaceutici S.p.A.
  acquired Amryt Pharma, a biopharmaceutical
  company focused on developing treatments for rare
  diseases. One of Amryt Pharma's prominent
  products is Mycapssa (octreotide capsules), which
  offers a new treatment option for acromegaly and
  neuroendocrine tumors, strengthening Chiesi's
  portfolio in the rare disease therapeutic space.
• In October 2022, Pfizer completed the acquisition
  of Biohaven Pharmaceutical Holding Company Ltd.,
  the developer of NURTEC ODT (rimegepant), a novel
  oral peptide therapy for migraine. This
  acquisition allowed Pfizer to expand its
  portfolio of innovative treatments for
  neurological conditions, especially for acute
  treatment and prevention of episodic migraines in
  adults.
• In December 2023, Pfizer received approval from
  Health Canada for NURTEC ODT (rimegepant) to
  treat acute migraines. This approval further
  extends the reach of the oral peptide,
  positioning it as an essential treatment option
  for patients suffering from episodic migraines
  and reinforcing Pfizers presence in the migraine
  treatment market.

sales_at_delvens.com
www.delvens.com
8
Contact Information
About Us Delvens is a strategic advisory and
consulting company headquartered in New Delhi,
India. The company holds expertise in providing
syndicated research reports, customized research
reports and consulting services. Delvens
qualitative and quantitative data is highly
utilized by each level from niche to major
markets, serving more than 1K prominent companies
by assuring to provide the information on
country, regional and global business
environment. We have a database for more than 45
industries in more than 115 major countries
globally. Contact Us 44-20-3290-6466 1
214-377-1144 sales_at_delvens.com
sales_at_delvens.com
www.delvens.com